Prostate cancer is the second leading cause of cancer deaths and the seventh overall cause of death in men in the United States (Centers for Disease Control and Prevention, 2008). Given that most new cases are diagnosed at an early, localized stage, significant attention has been focused on understanding the risks and benefits of alternative […]
Interventions of Interest: Factor VIII: Factor VIII concentrate is given intravenously, whether administered on-demand or prophylactically. Prophylaxis is administered multiple times per week, which is burdensome. Emicizumab (Hemlibra®, Genentech): a monoclonal antibody with dual targets that allow it to bridge activated factor IX and factor X, the role normally played by activated factor VIII in […]
Treatments of Interest: onasemnogene abeparvovec (Zolgensma®, Novartis AG/AveXis) nusinersen (Spinraza®, Biogen) Spinal muscular atrophy (SMA) is a rare, genetic neuromuscular disease. In its most common form, Type I SMA (~60% of cases), symptoms begin in infancy. Affected children never sit up, and they rapidly develop difficulty swallowing and breathing, eventually requiring feeding tubes and mechanical […]
Interventions of Interest inotersen (Tegsedi®, Akcea Therapeutics) patisiran (Onpattro®, Alnylam Pharmaceuticals) ICER reviewed new therapies for the treatment of hereditary transthyretin-related (hATTR) amyloidosis, a rare genetic condition characterized by nerve, heart, and eye damage that is currently treated through supportive measures alone. The Council voted unanimously that, despite the net health benefit, both inotersen and […]
2017 Interventions of Interest: TNF Inhibitors Adalimumab (Humira®, Abbvie) Certolizumab pegol (Cimzia®, UCB) Etanercept (Enbrel®, Amgen) Golimumab (Simponi®, Janssen) Infliximab (Remicade®, Janssen) CD20- Directed Cytolytic Antibody Rituximab (Rituxan®, Genentech) T Cell Inhibitor Abatacept (Orencia®, BMS) IL-6 Inhibitors Sarilumab (Kevzara®, Sanofi and Regeneron Pharmaceuticals) Tocilizumab (Actemra®, Genentech) JAK- Inhibitors Tofacitinib (Xeljanz®, Pfizer) Baricitinib (Olumiant®, Eli Lilly […]
Interventions of Interest: JAK- Inhibitors Baricitinib (Olumiant®, Eli Lilly and Co.) Tofacitinib (Xeljanz®, Pfizer) Upadacitinib (Rinvoq™, AbbVie) adalimumab (Humira®, AbbVie) Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults, affecting approximately 1.5 million Americans. RA is more common in women and may occur at any age, with peak incidence occurring at ages […]
Intervention of interest: Mepolizumab (Nucala®, GlaxoSmithKline plc.) An estimated 22 million Americans have asthma, which causes the airways of the lungs to narrow or become blocked, making it hard to breathe. Among both young and old, asthma can have a significant impact on health and limit the ability to pursue many activities. For questions, contact […]
Interventions of Interest Dupilumab (Dupixent®, Sanofi/Regeneron) Omalizumab (Xolair®, Genentech/Novartis) Mepolizumab (Nucala®, GlaxoSmithKline) Reslizumab (Cinqair®, Teva) Benralizumab (Fasenra™, AstraZeneca) An estimated 22 million Americans have asthma, which causes the airways of the lungs to narrow or become blocked, making it hard to breathe. Among both young and old, asthma can have a significant impact on health […]
Interventions of Interest: crisaborole (Eucrisa®, Pfizer, Inc.) dupilumab (Dupixent®, Sanofi and Regeneron, Inc.) Atopic dermatitis (eczema) is a chronic/chronically-relapsing skin condition characterized by itching and dry skin. Atopic dermatitis is common. It affects 5-20% of children worldwide, and approximately 11% of children in the US. It is also estimated to affect around 3-7% of adults […]
Interventions of interest: Antiarrhythmic drugs (amiodarone, dronedarone) Catheter ablation Surgical ablation Atrial fibrillation (AF) is the most common cardiac arrhythmia in the US population. AF occurs when rapid, disorganized electrical signals cause the atria (the two upper chambers of the heart) to “fibrillate”, or contract quickly and irregularly. This in turn causes some blood to […]